Novartis | NVS - Selling And Administration Expenses


Novartis reported $3.3B in Selling and Administration Expenses for its fiscal quarter ending in September of 2025.





Selling And Administration Expenses Change Date
AbbVie USD 3.89B 325M Dec/2025
Amgen USD 1.94B 237M Dec/2025
AstraZeneca USD 4.61B 4.46B Dec/2025
Bausch Health Companies USD 801M 6M Dec/2025
Biogen USD 545.2M 38.6M Sep/2025
Bristol-Myers Squibb USD 2.18B 392M Dec/2025
Canopy Growth CAD 29.53M 999K Sep/2025
Corcept Therapeutics USD 106.97M 3.12M Sep/2025
Drreddys Laboratories INR 26.92B 3.74B Dec/2025
Eli Lilly USD 3.13B 391.3M Dec/2025
Gilead Sciences USD 1.78B 425M Dec/2025
GlaxoSmithKline GBP 2.68B 518M Dec/2025
Glaxosmithkline GBP 2.91B 817.89M Sep/2025
J&J USD 6.75B 831M Dec/2025
Merck USD 2.85B 215M Dec/2025
Novartis USD 3.31B 134M Sep/2025
Novartis USD 3.3B 137M Sep/2025
Pacira USD 91.8M 14.6M Sep/2025
Perrigo USD 245.7M 27.4M Sep/2025
Pfizer USD 4.08B 894M Dec/2025
Phibro Animal Health USD 76.34M 10.54M Dec/2024
Prestige Brands USD 29.67M 1.64M Dec/2025
Roche Holding CHF 7.28B 3.99B Dec/2025
Sanofi EUR 2.75B 455M Dec/2025
Sanofi EUR 2.75B 455M Dec/2025
Supernus Pharmaceuticals USD 179.68M 117.46M Sep/2025
Zoetis USD 619M 40M Dec/2025